Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
vi. lappuse
... listed in the Finding Aids at the end of this volume . What if the material incorporated by reference cannot be found ? If you have any problem locating or obtaining a copy of material listed in the Finding Aids of this volume as an ...
... listed in the Finding Aids at the end of this volume . What if the material incorporated by reference cannot be found ? If you have any problem locating or obtaining a copy of material listed in the Finding Aids of this volume as an ...
7. lappuse
... listed in paragraph ( a ) of this section . ( c ) A fixed - combination prescription drug for humans that has been deter- mined to be effective for labeled indica- tions by the Food and Drug Adminis- tration , based on evaluation of the ...
... listed in paragraph ( a ) of this section . ( c ) A fixed - combination prescription drug for humans that has been deter- mined to be effective for labeled indica- tions by the Food and Drug Adminis- tration , based on evaluation of the ...
10. lappuse
... listed in these notices have been marketed under different names or by different firms during this same period or since 1962 without going through the new drug procedures or the Academy re- view . Even though these products are not listed ...
... listed in these notices have been marketed under different names or by different firms during this same period or since 1962 without going through the new drug procedures or the Academy re- view . Even though these products are not listed ...
21. lappuse
... listed in the current labeling for the drug product . This includes events that may be symptomatically and pathophysiologically related to an event listed in the labeling , but differ from the event because of greater se- verity or ...
... listed in the current labeling for the drug product . This includes events that may be symptomatically and pathophysiologically related to an event listed in the labeling , but differ from the event because of greater se- verity or ...
23. lappuse
... listed in the current label- ing for the drug product and includes an event that may be symptomatically and pathophysiologically related to an event listed in the labeling , but differs from the event because of greater severity or ...
... listed in the current label- ing for the drug product and includes an event that may be symptomatically and pathophysiologically related to an event listed in the labeling , but differs from the event because of greater severity or ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning